Inappropriate use of control switches in the genome may weaken our body's defenses against illness and could contribute to leukemia, according to a new study published in Frontiers in Immunology.
The research, led by Dr Anne Corcoran from the Babraham Institute in Cambridge, examines how the immune system makes antibodies, proteins that help to fight infections.
Blood Cancer Treatment Outcome Depends on Genetic Make Up of Proteins
The genetic make-up can impact the activity of the immune system and the body's ability to fight cancer.
Advertisement
‘A set of epigenetic marks and proteins behave like genetic switches and together control which genes contribute to making antibodies.’
Tweet it Now
The immune system can fight almost any infection by creating customised antibodies. Each antibody is made by combining a few genes from a large selection of possible components in a process called V(D)J recombination. Like building blocks, each combination of genes creates a unique antibody.
Some of these genetic building blocks are much more likely to be used by the immune system than others, and it is not clear why. This new study uses mice to identify for the first time a set of epigenetic marks and proteins, which behave like genetic switches and that together control which genes contribute to making antibodies.
![Acute Lymphoblastic Leukemia]( "Acute Lymphoblastic Leukemia")
Acute lymphoblastic leukemia (ALL) is the cancer of white blood cells characterized by excess lymphoblasts. It is the most common of all childhood cancers and can be fatal in weeks if left untreated.
The best antibodies are very precise in locking on to the causes of a particular illness. By combining genes in many different ways to make different antibodies, the immune system creates antibodies with the precision needed to identify and fight any possible infection.
Some people have genetic conditions that mean their immune system can not produce a large enough variety of antibodies, so they are less able to fight diseases. The immune system also weakens as we age. In both cases, changes to this newly discovered control mechanism could be partly responsible for these weaknesses.
The first author on the paper and postdoctoral researcher at the Babraham Institute, Dr Louise Matheson, said: "Our bodies are able to produce millions of different antibodies from just a few genes using V(D)J recombination, so it's an incredibly complex system. We wanted to understand how this process is controlled as well as which epigenetic marks and proteins are involved. By understanding these systems we can learn how to better control the immune system and how to help it fight infections."
Antibodies are made using several clusters of genes, called loci. This study focuses on just one locus in mice, known as immunoglobulin kappa. In mice and humans, the kappa locus contains around 140 genes for making parts of an antibody. By using a new method called VDJ-seq, a type of DNA sequencing, the researchers showed that the most commonly used antibody genes are labeled with specific histone methylations, a type of epigenetic mark. The team also found a link between the most active genes and two proteins called PU.1 and IKAROS.
The scientist that led the research, Dr Anne Corcoran, Group Leader at the Babraham Institute, said: "We have discovered some of the key factors that switch on the genes that make antibodies. This is a valuable insight into how the immune system protects our bodies, and what may be at fault when the immune system is weakened. This will ultimately help us to design diagnostic tests for people affected by recurrent infections and to devise therapies to boost the body's response to infection."
The team suggests that loss of the epigenetic marks and proteins highlighted by their study could contribute to the weakening of the immune system in old age and in some genetic conditions. If their future research can prove this, then it could lead to new treatments to strengthen the immune system and help more of us to stay healthy for longer into old age.
Source: Eurekalert
Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia (ALL) is the cancer of white blood cells characterized by excess lymphoblasts. It is the most common of all childhood cancers and can be fatal in weeks if left untreated.
Advertisement
The best antibodies are very precise in locking on to the causes of a particular illness. By combining genes in many different ways to make different antibodies, the immune system creates antibodies with the precision needed to identify and fight any possible infection.
Some people have genetic conditions that mean their immune system can not produce a large enough variety of antibodies, so they are less able to fight diseases. The immune system also weakens as we age. In both cases, changes to this newly discovered control mechanism could be partly responsible for these weaknesses.
The first author on the paper and postdoctoral researcher at the Babraham Institute, Dr Louise Matheson, said: "Our bodies are able to produce millions of different antibodies from just a few genes using V(D)J recombination, so it's an incredibly complex system. We wanted to understand how this process is controlled as well as which epigenetic marks and proteins are involved. By understanding these systems we can learn how to better control the immune system and how to help it fight infections."
Antibodies are made using several clusters of genes, called loci. This study focuses on just one locus in mice, known as immunoglobulin kappa. In mice and humans, the kappa locus contains around 140 genes for making parts of an antibody. By using a new method called VDJ-seq, a type of DNA sequencing, the researchers showed that the most commonly used antibody genes are labeled with specific histone methylations, a type of epigenetic mark. The team also found a link between the most active genes and two proteins called PU.1 and IKAROS.
The scientist that led the research, Dr Anne Corcoran, Group Leader at the Babraham Institute, said: "We have discovered some of the key factors that switch on the genes that make antibodies. This is a valuable insight into how the immune system protects our bodies, and what may be at fault when the immune system is weakened. This will ultimately help us to design diagnostic tests for people affected by recurrent infections and to devise therapies to boost the body's response to infection."
The team suggests that loss of the epigenetic marks and proteins highlighted by their study could contribute to the weakening of the immune system in old age and in some genetic conditions. If their future research can prove this, then it could lead to new treatments to strengthen the immune system and help more of us to stay healthy for longer into old age.
Source: Eurekalert
Arthritis Drug can Treat Rare Type of Blood Cancer
Polycythemia Vera is a rare type of blood disorder which has high blood cell count. Arthritis drug, methotrexate can effectively treat this disorder.
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Cancer News
The blood test pinpointed 13 proteins capable of distinguishing between early and late stages of pancreatic cancer.
A fatty acid present in dairy products, beef, and lamb called trans-vaccenic acid enhances immune cells' capacity to combat cancers.
Trametinib plus dabrafenib combined therapy demonstrated a clear therapeutic benefit in children with BRAF-mutated low- and high-grade gliomas.
Examining breast cancer occurrence and stages reveals disparities in urban versus rural rates, influenced by environmental conditions and the stage of the disease.
Polymerases theta and delta assist in the development of new cancer drugs known as polymerase theta inhibitors, currently undergoing clinical trials.